Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The biosimilar Ustekinumab has been developed and manufactured by the company
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Subscribe To Our Newsletter & Stay Updated
